Gastrointestinal Stromal Tumor (GIST) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Gastrointestinal Stromal Tumor (GIST) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastrointestinal Stromal Tumor (GIST) - Drugs In Development, 2022, provides an overview of the Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline landscape.

Gastrointestinal stromal tumors (GISTs) are tumors, which occur in the gastrointestinal tract. Gastrointestinal stromal tumors belong to a group of cancers called soft tissue sarcoma. GISTs can be benign or malignant tumors. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can feel with the hand, nausea and vomiting, vomiting blood or having blood in the stool and fatigue due to anemia (low red blood cell counts). Gastrointestinal stromal tumor treatment involves the use of surgery, radiation therapy, targeted therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastrointestinal Stromal Tumor (GIST) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 23, 21, 14, 4 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Gastrointestinal Stromal Tumor (GIST) – Overview
Gastrointestinal Stromal Tumor (GIST) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Gastrointestinal Stromal Tumor (GIST) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gastrointestinal Stromal Tumor (GIST) – Companies Involved in Therapeutics Development
AB Science SA
ABL Bio Inc
Advanced Accelerator Applications SA
Advenchen Laboratories LLC
Allarity Therapeutics Inc
Alligator Bioscience AB
Alyra Therapeutics Inc
Arog Pharmaceuticals Inc
Ascentage Pharma Group International
Bayer AG
BeiGene Ltd
Beijing Immunochina Pharmaceuticals Co Ltd
BioAtla Inc
Blueprint Medicines Corp
Calithera Biosciences Inc
Clarity Pharmaceuticals Ltd
Cogent Biosciences Inc
CStone Pharmaceuticals Co Ltd
DNAtrix Inc
Eisai Co Ltd
Eli Lilly and Co
Esperas Pharma Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Hanmi Pharmaceuticals Co Ltd
Hefei Cosource Pharmaceutical Inc
Horizon Therapeutics Plc
Hoth Therapeutics Inc
Idera Pharmaceuticals Inc
IDRx Inc
ImmunityBio Inc
Mendus AB
Merck & Co Inc
Merck KGaA
NewBay Medical Technology Co Ltd
Ningbo Tai Kang Medical Technology Co Ltd
Novartis AG
Novelty Nobility Inc
Omeros Corp
Pfizer Inc
Pharma Mar SA
Plexxikon Inc
Protheragen Inc
Qualigen Therapeutics Inc
Sartar Therapeutics Ltd
Shanghai Affinity Biomedical Technology Co Ltd
Shanghai Haihe Biopharma Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Shijiazhuang Yiling Pharmaceutical Co Ltd
Soricimed Biopharma Inc
Taivex Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Theseus Pharmaceuticals Inc
TotalClarity Inc
Virocure Inc
Gastrointestinal Stromal Tumor (GIST) – Drug Profiles
AAA-603 – Drug Profile
ABL-001 – Drug Profile
AL-8326 – Drug Profile
aldoxorubicin – Drug Profile
ALY-101 – Drug Profile
anagrelide hydrochloride CR – Drug Profile
anlotinib hydrochloride – Drug Profile
ATOR-1017 – Drug Profile
avapritinib – Drug Profile
avelumab – Drug Profile
axitinib – Drug Profile
AZD-3229 – Drug Profile
belvarafenib – Drug Profile
Bezuclastinib – Drug Profile
binimetinib – Drug Profile
BLU-654 – Drug Profile
Cabometyx – Drug Profile
Cellular Immunotherapy for Oncology – Drug Profile
CHMFLKIT-110 – Drug Profile
CHMFLKIT-64 – Drug Profile
crenigacestat – Drug Profile
crenolanib besylate – Drug Profile
CS-2164 – Drug Profile
dabrafenib mesylate – Drug Profile
dabrafenib mesylate + trametinib dimethyl sulfoxide – Drug Profile
DNX-2440 – Drug Profile
dovitinib lactate – Drug Profile
doxorubicin – Drug Profile
ESP-01 – Drug Profile
GPCR-targeted Project 010 – Drug Profile
HT-KIT – Drug Profile
HYGT-110 – Drug Profile
IDRX-42 – Drug Profile
IM-24 – Drug Profile
interferon gamma-1b – Drug Profile
ipilimumab biosimilar – Drug Profile
larotrectinib sulfate – Drug Profile
lenvatinib mesylate – Drug Profile
llixadencel – Drug Profile
LP-650 – Drug Profile
masitinib – Drug Profile
Monoclonal Antibody Conjugates to Target CD117 for Gastrointestinal Stromal Tumor – Drug Profile
NB-003 – Drug Profile
NN-3201 – Drug Profile
NN-3202 – Drug Profile
nofazinlimab – Drug Profile
olverembatinib – Drug Profile
ozuriftamab vedotin – Drug Profile
pembrolizumab – Drug Profile
pexidartinib hydrochloride – Drug Profile
plocabulin – Drug Profile
ponatinib hydrochloride – Drug Profile
QN-302 – Drug Profile
RC-402 – Drug Profile
regorafenib – Drug Profile
rogaratinib – Drug Profile
SAR-BBN – Drug Profile
simmitecan hydrochloride – Drug Profile
Small Molecule to Antagonize GPR20 for Acute Myeloid Leukemia and Gastro-Intestinal Stromal Tumors – Drug Profile
Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor – Drug Profile
SORC-13 – Drug Profile
spartalizumab – Drug Profile
T-1301 – Drug Profile
TCONC-51 – Drug Profile
telaglenastat hydrochloride – Drug Profile
THE-630 – Drug Profile
tilsotolimod sodium – Drug Profile
tislelizumab – Drug Profile
TNO-155 – Drug Profile
vemurafenib – Drug Profile
XY-0206 – Drug Profile
Gastrointestinal Stromal Tumor (GIST) – Dormant Projects
Gastrointestinal Stromal Tumor (GIST) – Discontinued Products
Gastrointestinal Stromal Tumor (GIST) – Product Development Milestones
Featured News & Press Releases
Jun 06, 2022: ASCO 2022 | The First dataset of Olverembatinib (HQP1351) in patients with GIST demonstrates therapeutic potential with a clinical benefit rate of 83.3%
Apr 28, 2022: Ascentage Pharma to present data on Olverembatinib at the 2022 American Society of Clinical Oncology Annual Meeting
Apr 11, 2022: Cogent Biosciences presents nonclinical data at AACR Annual Meeting and provides updates on portfolio expansion at R&D Investor Event
Mar 29, 2022: Cogent Biosciences to host Virtual R&D Investor Event
Mar 08, 2022: Blueprint Medicines to showcase poster presentation on selective KIT V654A inhibitor at AACR Annual Meeting 2022
Mar 08, 2022: Cogent Biosciences announces upcoming presentations at AACR annual meeting 2022
Feb 17, 2022: EMA recommends extension of therapeutic indications for avapritinib
Dec 28, 2021: CStone announced new drug approval of precision therapy AYVAKIT (avapritinib) in Hong Kong, China for the treatment of PDGFRA D842V mutant gastrointestinal stromal tumors (GIST)
Oct 01, 2021: Cogent Biosciences to present preclinical data on bezuclastinib at AACR-NCI-EORTC Conference
Aug 05, 2021: ESMO: Avapritinib not superior to Regorafenib in terms of median PFS in third-line or later treatment of patients with unresectable or metastatic GIST
Jul 08, 2021: CStone announces updated results for AYVAKIT(R) (avapritinib) in Chinese patients with advanced GIST at ESMO World Congress on Gastrointestinal Cancer 2021
Jun 03, 2021: Hoth Therapeutics shares positive preclinical results of novel HT-KIT therapeutic
May 24, 2021: Hoth Therapeutics announces participation at the American Society of Clinical Oncology (ASCO) Annual Meeting, to discuss on HT-KIT
May 22, 2021: CStone Pharmaceuticals holds the First Tumor Precision Therapy Forum and Taijihua China Listing Conference
May 12, 2021: CStone Pharmaceuticals announced that the new drug application for Avapritinib has been accepted in Hong Kong for the treatment of adult patients with unresectable or metastatic GIST with PDGFRA D842V mutation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
Table 5: Number of Products under Development by Universities/Institutes, 2022
Table 6: Products under Development by Companies, 2022
Table 7: Products under Development by Companies, 2022 (Contd..1)
Table 8: Products under Development by Companies, 2022 (Contd..2)
Table 9: Products under Development by Companies, 2022 (Contd..3)
Table 10: Products under Development by Universities/Institutes, 2022
Table 11: Number of Products by Stage and Target, 2022
Table 12: Number of Products by Stage and Target, 2022 (Contd..1)
Table 13: Number of Products by Stage and Target, 2022 (Contd..2)
Table 14: Number of Products by Stage and Mechanism of Action, 2022
Table 15: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Table 16: Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)
Table 17: Number of Products by Stage and Route of Administration, 2022
Table 18: Number of Products by Stage and Molecule Type, 2022
Table 19: Gastrointestinal Stromal Tumor (GIST) – Pipeline by AB Science SA, 2022
Table 20: Gastrointestinal Stromal Tumor (GIST) – Pipeline by ABL Bio Inc, 2022
Table 21: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Advanced Accelerator Applications SA, 2022
Table 22: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Advenchen Laboratories LLC, 2022
Table 23: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Allarity Therapeutics Inc, 2022
Table 24: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Alligator Bioscience AB, 2022
Table 25: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Alyra Therapeutics Inc, 2022
Table 26: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Arog Pharmaceuticals Inc, 2022
Table 27: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Ascentage Pharma Group International, 2022
Table 28: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Bayer AG, 2022
Table 29: Gastrointestinal Stromal Tumor (GIST) – Pipeline by BeiGene Ltd, 2022
Table 30: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Beijing Immunochina Pharmaceuticals Co Ltd, 2022
Table 31: Gastrointestinal Stromal Tumor (GIST) – Pipeline by BioAtla Inc, 2022
Table 32: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Blueprint Medicines Corp, 2022
Table 33: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Calithera Biosciences Inc, 2022
Table 34: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Clarity Pharmaceuticals Ltd, 2022
Table 35: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Cogent Biosciences Inc, 2022
Table 36: Gastrointestinal Stromal Tumor (GIST) – Pipeline by CStone Pharmaceuticals Co Ltd, 2022
Table 37: Gastrointestinal Stromal Tumor (GIST) – Pipeline by DNAtrix Inc, 2022
Table 38: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Eisai Co Ltd, 2022
Table 39: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Eli Lilly and Co, 2022
Table 40: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Esperas Pharma Inc, 2022
Table 41: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Exelixis Inc, 2022
Table 42: Gastrointestinal Stromal Tumor (GIST) – Pipeline by F. Hoffmann-La Roche Ltd, 2022
Table 43: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
Table 44: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Hefei Cosource Pharmaceutical Inc, 2022
Table 45: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Horizon Therapeutics Plc, 2022
Table 46: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Hoth Therapeutics Inc, 2022
Table 47: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Idera Pharmaceuticals Inc, 2022
Table 48: Gastrointestinal Stromal Tumor (GIST) – Pipeline by IDRx Inc, 2022
Table 49: Gastrointestinal Stromal Tumor (GIST) – Pipeline by ImmunityBio Inc, 2022
Table 50: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Mendus AB, 2022
Table 51: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Merck & Co Inc, 2022
Table 52: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Merck KGaA, 2022
Table 53: Gastrointestinal Stromal Tumor (GIST) – Pipeline by NewBay Medical Technology Co Ltd, 2022
Table 54: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Ningbo Tai Kang Medical Technology Co Ltd, 2022
Table 55: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Novartis AG, 2022
Table 56: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Novelty Nobility Inc, 2022
Table 57: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Omeros Corp, 2022
Table 58: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Pfizer Inc, 2022
Table 59: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Pharma Mar SA, 2022
Table 60: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Plexxikon Inc, 2022
Table 61: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Protheragen Inc, 2022
Table 62: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Qualigen Therapeutics Inc, 2022
Table 63: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Sartar Therapeutics Ltd, 2022
Table 64: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Shanghai Affinity Biomedical Technology Co Ltd, 2022
Table 65: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Shanghai Haihe Biopharma Co Ltd, 2022
Table 66: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
Table 67: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Shijiazhuang Yiling Pharmaceutical Co Ltd, 2022
Table 68: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Soricimed Biopharma Inc, 2022
Table 69: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Taivex Therapeutics Inc, 2022
Table 70: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Table 71: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Theseus Pharmaceuticals Inc, 2022
Table 72: Gastrointestinal Stromal Tumor (GIST) – Pipeline by TotalClarity Inc, 2022
Table 73: Gastrointestinal Stromal Tumor (GIST) – Pipeline by Virocure Inc, 2022
Table 74: Gastrointestinal Stromal Tumor (GIST) – Dormant Projects, 2022
Table 75: Gastrointestinal Stromal Tumor (GIST) – Dormant Projects, 2022 (Contd..1)
Table 76: Gastrointestinal Stromal Tumor (GIST) – Discontinued Products, 2022
Table 77: Gastrointestinal Stromal Tumor (GIST) – Discontinued Products, 2022 (Contd..1)
List of Figures
Figure 1: Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products under Development by Universities/Institutes, 2022
Figure 4: Number of Products by Top 10 Targets, 2022
Figure 5: Number of Products by Stage and Top 10 Targets, 2022
Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 8: Number of Products by Top 10 Routes of Administration, 2022
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, 2022
Figure 10: Number of Products by Top 10 Molecule Types, 2022
Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings